BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy  

作　　者：Wei Zhang Dan Liu Tao Zhang Jiang Cao Gang Wang Huizhong Li Su Zhou Ruixue Zhang Yuqiao Wang Jinyu Li Zixuan Zhang Hao Chen Yong Zhang Shenyang Zhang Jie Zu Xiaopeng Wang Chuanying Xu Manli Zhou Ming Shi Guiyun Cui Junnian Zheng 

机构地区：[1]Department of Neurology,The Affiliated Hospital of Xuzhou Medical University,Jiangsu,China [2]Cancer Institute,Xuzhou Medical University,Jiangsu,China [3]Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy,Xuzhou Medical University,Jiangsu,China [4]Center of Clinical Oncology,The Affiliated Hospital of Xuzhou Medical University,Jiangsu,China [5]Department of Hematology,The Affiliated Hospital of Xuzhou Medical University,Jiangsu,China

出　　处：《hLife》2024年第8期434-438,共5页健康科学（英文）

基　　金：support from the National Natural Science Foundation of China(81972719,82273207).

摘　　要：Chronic inflammatory demyelinating polyneuropathy(CIDP)is a rare immune-mediated disease characterized by refractory and relapsed peripheral nerve and nerve root damage,leading to severe sequelae for patients.Although glucocorticoids,intravenous immunoglobulin(IVIg),and immunosuppressive agents are recommended for treating CIDP and preventing relapses,some patients’conditions cannot be effectively controlled.Due to the uncertain efficacy and toxicity issues of broad-spectrum immune-modulatory or suppressive drugs,developing a safe and effective treatment strategy is warranted.

关 键 词：MYELIN DRUGS POLYNEUROPATHY 

分 类 号：R745[医药卫生—神经病学与精神病学]